✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
LCB01-0371 is an investigational drug.
There have been 11 clinical trials for LCB01-0371. The most recent clinical trial was a Phase 2 trial, which was initiated on December 10th 2016.
The most common disease conditions in clinical trials are Tuberculosis, Pulmonary, Tuberculosis, and Infection. The leading clinical trial sponsors are LegoChem Biosciences, Inc, Ludwig-Maximilians - University of Munich, and Radboud University.
There are three US patents protecting this investigational drug and twenty international patents.
Recent Clinical Trials for LCB01-0371
|A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia||LegoChem Biosciences, Inc||Phase 2|
|PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)||Ludwig-Maximilians - University of Munich||Phase 2|
|PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)||Radboud University||Phase 2|
Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LCB01-0371||See Plans and Pricing||Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof||Legochem Biosciences, Inc. (Deajeon, KR)||See Plans and Pricing|
|LCB01-0371||See Plans and Pricing||Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use||Trius Therapeutics, Inc. (San Diego, CA)||See Plans and Pricing|
|LCB01-0371||See Plans and Pricing||Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives||Legochem Biosciences, Inc. (Daejeon, KR)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|LCB01-0371||Australia||AU2009297294||2028-09-24||See Plans and Pricing|
|LCB01-0371||Brazil||BRPI0918964||2028-09-24||See Plans and Pricing|
|LCB01-0371||Canada||CA2737299||2028-09-24||See Plans and Pricing|
|LCB01-0371||China||CN102171207||2028-09-24||See Plans and Pricing|
|LCB01-0371||European Patent Office||EP2331529||2028-09-24||See Plans and Pricing|
|LCB01-0371||Spain||ES2526120||2028-09-24||See Plans and Pricing|
|LCB01-0371||Japan||JP2012503599||2028-09-24||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|